cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Alnylam Pharmaceuticals Inc
7 own
12 watching
Current Price
$233.37
$3.62
(1.58%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
28,702.41M
52-Week High
52-Week High
242.97
52-Week Low
52-Week Low
117.58
Average Volume
Average Volume
1.21M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization28,702.41M
icon52-Week High242.97
icon52-Week Low117.58
iconAverage Volume1.21M
iconDividend Yield--
iconP/E Ratio--
What does the Alnylam Pharmaceuticals Inc do?
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Alnylam Pharmaceuticals Inc make?
News & Events about Alnylam Pharmaceuticals Inc.
Business Wire
1month ago
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic...
TheStreet.com
1month ago
Avidity Biosciences roared higher after announcing favorable data delivering RNA medicines to muscle tissue.Avidity Biosciences roared higher after announcing favorable data delivering RNA medicines to muscle tissue.Hours after Alex Ovechkin became the first NHL player to score 800 goals with one ...
Business Wire
2 months ago
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 2:05 pm GMT (9:05 am ET) at the Waldorf Hilton...
Business Wire
3 months ago
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its second place ranking in Science Magazines 2022 Top Employer Survey. This marks the fourth year Alnylam was featured as one of the top three companies in the annual survey of more than 6,200...
Business Wire
4 months ago
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved a label expansion for OXLUMO (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of...
Frequently Asked Questions
Frequently Asked Questions
What is Alnylam Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Alnylam Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Alnylam Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Alnylam Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Alnylam Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Alnylam Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Alnylam Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Alnylam Pharmaceuticals Inc?
plus_minus_icon
What percentage is Alnylam Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Alnylam Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$233.37
$3.62
(1.58%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00